VEGFA and cancer: In contrast, M2 macrophages, which are characterized by the release of pro-angiogenic mediators such as vascular endothelial growth factor (VEGF) and immunosuppressive cytokines such as IL-10 and transforming growth factor-β, are generally correlated with poor prognosis among cancer patients (1, 3).